List

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until April, 2020.

  1. Therapeutic D-peptide Inhibitor of HIV Entry

    SBC: NAVIGEN, INC.            Topic: NIAID

    DESCRIPTION provided by applicant With million people living with HIV AIDS including million in the US and million AIDS related deaths annually HIV AIDS remains a formidable global epidemic UNAIDS CDC Modern HIV therapy combines drugs from different classes to form andquot cocktailandquot therapies that have significantly prolonged the lives of many HIV patients However side effects and drug resis ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  2. Broad Spectrum Antiviral Nucleoside Phosphonate Analogs

    SBC: TSRL, INC.            Topic: NIAID

    DESCRIPTION provided by applicant The Working Group for Civilian Biodefense reviewed potential biological threat agents and listed those considered to pose the greatest threat to the civilian population Variola and other orthopox DNA viruses were identified as a potential bioterrorism threat Additionally other DNA viruses are of increasing concern in a public health context due to the emerge ...

    SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  3. Protease resistant D peptide Inhibitors of Ebola Virus Entry

    SBC: NAVIGEN, INC.            Topic: R

    DESCRIPTION provided by applicant Ebola virus causes highly lethal hemorrhagic fever in humans and non human primates Since the first outbreak in there have been over natural human outbreaks with an average mortality rate near There are no approved agents to prevent or treat Ebola infection Due to ease of dissemination high lethality and ability to cause widespread panic the ...

    SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  4. Synthetic microparticle malaria vaccine

    SBC: ARTIFICIAL CELL TECHNOLOGIES INC            Topic: NIAID

    DESCRIPTION provided by applicant This Phase II project will develop a novel synthetic microparticle vaccine for malaria using the T BT epitopes of the circumsporozoite CS protein of Plasmodium falciparum the causative agent of human malaria There is no approved vaccine for malaria a disease that causes up to million new infections and million deaths each year in the developing wor ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  5. BPN Safety and Cognitive Effect in Young and Elderly Subjects

    SBC: TETRA DISCOVERY PARTNERS, INC.            Topic: NIA

    Project Abstract Tetra Discovery Partners is seeking Phase II SBIR funding for a multiple ascending dose human Phase clinical trial of BPN to evaluate safety tolerability pharmacokinetic and cognitive profile in healthy young and elderly male and female subjects BPN is a first in class phosphodiesterase D negative allosteric modulator PDE D NAM that targets the protein kinase A ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Non-Invasive Treatment for Uveitis

    SBC: ACIONT, INC.            Topic: N

    DESCRIPTION provided by applicant The aim of this innovative proposal is to commercialize a non invasive topical product that treats uveitis which is safe and easy to administer Uveitis is the third leading cause of blindness in the United States Heretofore the primary treatment of intermediate and posterior uveitis has been either oral medications with significant systemic side effects or ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  7. SYSTEMIC RADIONUCLIDE THERAPY TARGETED TO VEGF RECEPTORS IN TUMOR VASCULATURE

    SBC: SIBTECH, INC.            Topic: NCI

    The overall goal of this collaborative project between SibTech Inc PI Backer J and Johns Hopkins University PI Pomper M is clinical development of efficient and cost effective anti angiogenic Lu radiopharmaceutical scV Lu for VEGF receptor mediated targeting of angiogenic tumor vasculature Current very expensive anti angiogenic compounds induce transient regression of tumor vascula ...

    SBIR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  8. PREDICTIVE BIOMARKERS OF ADVERSE REACTIONS TO PROSTRATE CANCER RADIOTHERAPY

    SBC: L2 DIAGNOSTICS, LLC            Topic: NCI

    The overall objective of this project is to advance the development of a clinically usefully multiplex assay todetect biomarkers of radio sensitivity that will identify subsets of prostate cancer patients for whichradiotherapy should be contraindicated This assay will be capable of predicting the risk of developingadverse effects principally urinary morbidity and rectal injury resulting from ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  9. Novel Micro-Implant to Measure Intracardiac Pressure in Congenital Heart Patients

    SBC: Integrated Sensing Systems Incorporated            Topic: NHLBI

    DESCRIPTION provided by applicant PROJECT SUMMARY Congenital heart disease patients with functional single ventricle FSV anatomy ultimately require a Fontan operation for long term survival The goal of the Fontan operation is to re route systemic venous blood to the pulmonary circulation without passing through an intervening ventricular chamber As a result blood flow to the lungs is almos ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Diagnostic Assays for early Lyme Borreliosis using in-vivo expressed antigens

    SBC: L2 DIAGNOSTICS, LLC            Topic: NIAID

    DESCRIPTION provided by applicant Current testing for Lyme disease is suboptimal because it requires two assay platforms including one with subjective interpretation of results and because it has lower sensitivity in the early stage of the illness Infection with Borrelia burgdorferi the causative agent of Lyme disease is transmitted by the bite of an Ixodid tick and results in uniformly lo ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government